Pharmaceutical Breakthrough for the Treatment of Duchenne Muscular Dystrophy

5 years ago

By: Rubab Hassan, PharmD Candidate c/o 2022              Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscle degeneration…

Bamlanivimab for the treatment of COVID-19

5 years ago

By: Daniela Farzadfar, PharmD,PGY-1 Resident at Long Island Jewish Medical Center              In March 2020, the World Health Organization (WHO)…

Insulin Monitoring System for Pediatric patients

5 years ago

By: Lyana Sayilar, PharmD Candidate c/o 2022              On August 31, 2020, the FDA approved the first automated diabetes management…

Who is COVID-19 hitting the hardest?

5 years ago

By: Pooja Dasgupta and Sonya Wadhawan, PharmD Candidates c/o 2025              The coronavirus, also known as SARS CoV-2 or COVID-19,…

The Cardiovascular Effects of Cannabis vs. Tobacco Consumption

5 years ago

By: Jeng Lee, PharmD Candidate c/o 2022               Throughout the past decade, there has been an increase in the prevalence…

New Drug Update: Lemborexant (Dayvigo ®)

5 years ago

By: Cindy Van, PharmD Candidate c/o 2022, Shireen Farzadeh, PharmD, BCPS              Insomnia is a condition characterized by difficulty falling…

Rybelsus: Novel Oral GLP-1 Agonist and the Future of Oral Protein Dosage Forms

5 years ago

By: Tanay Maddula PharmD Candidate c/o 2022               Rybelsus (oral semaglutide) was recently approved by the Food and Drug Administration…

Fostemsavir: New drug for the treatment of HIV-1 resistant patients

5 years ago

By: Bisma Sekhery, PharmD Candidate c/o 2021              Fostemsavir (Rukobia) is a new Food and Drug Administration (FDA) approved antiretroviral…

Emerging Type 3 Diabetes

5 years ago

By: Zarnab Jillani PharmD Candidate c/o 2022              The link between diabetes and Alzheimer’s disease (AD) is a new and…

Increasing Evidence of the Benefits of Statins

5 years ago

By: Pallak Sharma, PharmD Candidate c/o 2022 and Rebecca Samuel, PharmD Candidate c/o 2022              Statins, some of the most…